This minor group of patients responded not the same way as the majority of HNSCC samples analyzed as they did not show suppression of MCP-1, IFN-γ, and IL-6 production by pembrolizumab + TP. The gene discussed is CCL2; the disease is head and neck squamous cell carcinoma.